SlideShare a Scribd company logo
1 of 1
Download to read offline
Medicinal plants and natural products in
pharmaceutical practice in Costa RicaAuthors
Hall, V1; Rocha, M1
1Pharmacist at National Drug Information Center (CIMED®) INIFAR Pharmacy Faculty University of Costa Rica1Pharmacist at National Drug Information Center (CIMED®). INIFAR. Pharmacy Faculty, University of Costa Rica
Contact details: victoria.hall@ucr.ac.cr
I.Background
In Costa Rica, national legislation (Decree No. 29315-S) defines natural
product with medicinal qualities as finished products and labeled those
whose ingredient (s) active (s), organic or inorganic from plants, animals
or the kingdom mineral and may contain excipients, presenting with
medicinal qualities
17.50%
5.00%
Once a week
Twice a week
Three times a week
Graphic No.1 Frequency of inquiries about medicinal plants and
natural products received by pharmacists in their daily practice
medicinal qualities.
During 2012, 18.66% of the inquiries received by the National Drug
Information Center (Centro Nacional de Información de Medicamentos, or
CIMED®) were about medicinal plants and natural products.
II.Aims
Describe the type of inquiries about medicinal plants and natural products
that are made to pharmacists in their daily practice and the sources of
52.50%
7.50%
5.00%
10.00%
2.50% Four times a week
Five times a week
More than five time a
week
Never
G hi N 2 T f i i i i d b h i t b t
information they used to resolve them.
III.Methods
_Type of study: Descriptive
_Method: An electronic survey was developed. It was posted on CIMED´s
Facebook page for 2 weeks. The results were tabulated and analyzed.
IV.Results
About 40 pharmacist answered the electronic survey The field they are
10
7
7
5
3
3
1
Lactation considerations
Use in pediatrics
Use in geriatrics
Other
Mechanism of action
Herbal interactions
Food interactions
Graphic No. 2 Type of inquiries received by pharmacists about
medicinal plants and natural products in their daily practice
About 40 pharmacist answered the electronic survey. The field they are
currently working is the following: 42.5% in private pharmacies, 22.5% in
community and public pharmacies (they belong to Social Security or
CCSS), 10% in hospital pharmacies, 10% in regulatory affairs, 5% in
research and development and the other 10% in medical visit and
universities.
The 52.5% of professionals indicated that they receive at least once a
34
20
20
15
15
14
10
0 5 10 15 20 25 30 35 40
Use
Dosage and route of administration
Drug interactions
Contraindications
Pregnancy considerations
Adverse reactions
Precautions
Graphic No. 3 Health problems associated with the inquiries
received by pharmacists about medicinal plants and natural
week, an inquiry about medicinal plants (MP) and natural products (NP).
The 67.5% of professionals use MP an NP to treat their own health
problems and 15.2% uses at least 1 MP or NP every day.
The 37.5% of pharmacists use the internet (unspecified site) to resolve
inquiries; scientific and objective references such PubMed or Drug
Information Handbook are used by 37.5% of pharmacists and 10% uses
14
14
9
6
6
5
2
0
Cardiovascular diseases
Pain and inflammation
Other
Genitourinary problems
Infections
Skin problems
Eye problems
Ear problems
received by pharmacists about medicinal plants and natural
products in their daily practice
no reference at all. The 95% of pharmacist are interested in receiving
training and updating on the issue of MP and NP.
V.Conclusions
Consultations on MP and NP are multiple and complex, as with drugs.
Based on the results, not all pharmacists have all the information and
t i i t id th ti t di th f th MP d
30
27
24
16
0 5 10 15 20 25 30 35
Obesity
Insomnia
Digestive problems
Respiratory problems
training necessary to guide the patient regarding the use of the MP and
NP, but shows interest in acquiring.
Acknowledgements
Special acknowledgement for the Pharmaceutical Research Institute (INFAR)
and Pharmacy Faculty of University of Costa Rica for their support.

More Related Content

What's hot

What's hot (20)

Spontaneous reporting
Spontaneous reportingSpontaneous reporting
Spontaneous reporting
 
Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drug
Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan DrugConnecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drug
Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drug
 
Orphan Drug 101
Orphan Drug 101Orphan Drug 101
Orphan Drug 101
 
Health Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand PirouziHealth Canada Progressive Licensing - Professor Peivand Pirouzi
Health Canada Progressive Licensing - Professor Peivand Pirouzi
 
What is an orphan drug?
What is an orphan drug?What is an orphan drug?
What is an orphan drug?
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Niche buster drug
Niche buster drugNiche buster drug
Niche buster drug
 
MeTA Baseline Assessments
MeTA Baseline AssessmentsMeTA Baseline Assessments
MeTA Baseline Assessments
 
Pharmacovigilance and adr
Pharmacovigilance and adrPharmacovigilance and adr
Pharmacovigilance and adr
 
Saudi Moh formulary
Saudi Moh formularySaudi Moh formulary
Saudi Moh formulary
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pv
 
Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...Safety monitoring and reporting of adverse events of medical devices national...
Safety monitoring and reporting of adverse events of medical devices national...
 
Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015
 
Pharmacovigilance Training in Oracle Argus Safety Database
Pharmacovigilance Training in Oracle Argus Safety DatabasePharmacovigilance Training in Oracle Argus Safety Database
Pharmacovigilance Training in Oracle Argus Safety Database
 
Setting up of new pharmacovigilance centres
Setting up of new pharmacovigilance centresSetting up of new pharmacovigilance centres
Setting up of new pharmacovigilance centres
 
How to report an SAE
How to report an SAEHow to report an SAE
How to report an SAE
 
Pharmacovigilance Establishment in India and An overview on PvPI
Pharmacovigilance Establishment in India and An overview on PvPIPharmacovigilance Establishment in India and An overview on PvPI
Pharmacovigilance Establishment in India and An overview on PvPI
 
The regulation of complementary medicines
The regulation of complementary medicinesThe regulation of complementary medicines
The regulation of complementary medicines
 
STREAM TWO: Larissa Lapteva, Medical Product Development For Rare Diseases Pa...
STREAM TWO: Larissa Lapteva, Medical Product Development For Rare Diseases Pa...STREAM TWO: Larissa Lapteva, Medical Product Development For Rare Diseases Pa...
STREAM TWO: Larissa Lapteva, Medical Product Development For Rare Diseases Pa...
 

Similar to Poster plantas para entregar

Herbal products in canada how safe are they
Herbal products in canada how safe are theyHerbal products in canada how safe are they
Herbal products in canada how safe are they
Nazeer Mohd
 
5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)
Teleosis Institute
 
Pme lecture 2012presentation part2
Pme lecture 2012presentation part2Pme lecture 2012presentation part2
Pme lecture 2012presentation part2
University of Miami
 
Revisedpart iipme lecture 2012presentationpart2
Revisedpart iipme lecture 2012presentationpart2Revisedpart iipme lecture 2012presentationpart2
Revisedpart iipme lecture 2012presentationpart2
University of Miami
 

Similar to Poster plantas para entregar (20)

Herbal products in canada how safe are they
Herbal products in canada how safe are theyHerbal products in canada how safe are they
Herbal products in canada how safe are they
 
Usfda swatee
Usfda swateeUsfda swatee
Usfda swatee
 
Botanical Drug Development
Botanical Drug DevelopmentBotanical Drug Development
Botanical Drug Development
 
Safety Monitoring of Natural Medicine
Safety Monitoring of Natural MedicineSafety Monitoring of Natural Medicine
Safety Monitoring of Natural Medicine
 
5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)5.2. Reason for Concern (Batz)
5.2. Reason for Concern (Batz)
 
Pme lecture 2012presentation part2
Pme lecture 2012presentation part2Pme lecture 2012presentation part2
Pme lecture 2012presentation part2
 
Usfda
UsfdaUsfda
Usfda
 
WHO guidelines on herbal drug monitoring
WHO guidelines on herbal drug monitoringWHO guidelines on herbal drug monitoring
WHO guidelines on herbal drug monitoring
 
Revisedpart iipme lecture 2012presentationpart2
Revisedpart iipme lecture 2012presentationpart2Revisedpart iipme lecture 2012presentationpart2
Revisedpart iipme lecture 2012presentationpart2
 
clinical pharmacy
clinical pharmacyclinical pharmacy
clinical pharmacy
 
Madhu k s
Madhu k s Madhu k s
Madhu k s
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpments
 
Drug information services by BNP.pdf
Drug information services by BNP.pdfDrug information services by BNP.pdf
Drug information services by BNP.pdf
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Drug information center (dic)
Drug information center (dic)Drug information center (dic)
Drug information center (dic)
 
Quality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptxQuality, Safety and Legislation for herbal products in USA.pptx
Quality, Safety and Legislation for herbal products in USA.pptx
 
Usfda sana 1
Usfda sana 1Usfda sana 1
Usfda sana 1
 
MHRA and USFDA simultaneously data
MHRA and USFDA simultaneously dataMHRA and USFDA simultaneously data
MHRA and USFDA simultaneously data
 
Roshan (1)
Roshan (1)Roshan (1)
Roshan (1)
 

Poster plantas para entregar

  • 1. Medicinal plants and natural products in pharmaceutical practice in Costa RicaAuthors Hall, V1; Rocha, M1 1Pharmacist at National Drug Information Center (CIMED®) INIFAR Pharmacy Faculty University of Costa Rica1Pharmacist at National Drug Information Center (CIMED®). INIFAR. Pharmacy Faculty, University of Costa Rica Contact details: victoria.hall@ucr.ac.cr I.Background In Costa Rica, national legislation (Decree No. 29315-S) defines natural product with medicinal qualities as finished products and labeled those whose ingredient (s) active (s), organic or inorganic from plants, animals or the kingdom mineral and may contain excipients, presenting with medicinal qualities 17.50% 5.00% Once a week Twice a week Three times a week Graphic No.1 Frequency of inquiries about medicinal plants and natural products received by pharmacists in their daily practice medicinal qualities. During 2012, 18.66% of the inquiries received by the National Drug Information Center (Centro Nacional de Información de Medicamentos, or CIMED®) were about medicinal plants and natural products. II.Aims Describe the type of inquiries about medicinal plants and natural products that are made to pharmacists in their daily practice and the sources of 52.50% 7.50% 5.00% 10.00% 2.50% Four times a week Five times a week More than five time a week Never G hi N 2 T f i i i i d b h i t b t information they used to resolve them. III.Methods _Type of study: Descriptive _Method: An electronic survey was developed. It was posted on CIMED´s Facebook page for 2 weeks. The results were tabulated and analyzed. IV.Results About 40 pharmacist answered the electronic survey The field they are 10 7 7 5 3 3 1 Lactation considerations Use in pediatrics Use in geriatrics Other Mechanism of action Herbal interactions Food interactions Graphic No. 2 Type of inquiries received by pharmacists about medicinal plants and natural products in their daily practice About 40 pharmacist answered the electronic survey. The field they are currently working is the following: 42.5% in private pharmacies, 22.5% in community and public pharmacies (they belong to Social Security or CCSS), 10% in hospital pharmacies, 10% in regulatory affairs, 5% in research and development and the other 10% in medical visit and universities. The 52.5% of professionals indicated that they receive at least once a 34 20 20 15 15 14 10 0 5 10 15 20 25 30 35 40 Use Dosage and route of administration Drug interactions Contraindications Pregnancy considerations Adverse reactions Precautions Graphic No. 3 Health problems associated with the inquiries received by pharmacists about medicinal plants and natural week, an inquiry about medicinal plants (MP) and natural products (NP). The 67.5% of professionals use MP an NP to treat their own health problems and 15.2% uses at least 1 MP or NP every day. The 37.5% of pharmacists use the internet (unspecified site) to resolve inquiries; scientific and objective references such PubMed or Drug Information Handbook are used by 37.5% of pharmacists and 10% uses 14 14 9 6 6 5 2 0 Cardiovascular diseases Pain and inflammation Other Genitourinary problems Infections Skin problems Eye problems Ear problems received by pharmacists about medicinal plants and natural products in their daily practice no reference at all. The 95% of pharmacist are interested in receiving training and updating on the issue of MP and NP. V.Conclusions Consultations on MP and NP are multiple and complex, as with drugs. Based on the results, not all pharmacists have all the information and t i i t id th ti t di th f th MP d 30 27 24 16 0 5 10 15 20 25 30 35 Obesity Insomnia Digestive problems Respiratory problems training necessary to guide the patient regarding the use of the MP and NP, but shows interest in acquiring. Acknowledgements Special acknowledgement for the Pharmaceutical Research Institute (INFAR) and Pharmacy Faculty of University of Costa Rica for their support.